Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis
- PMID: 20196680
- DOI: 10.3109/10731191003634778
Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis
Abstract
Background: The binding of anti-acetylcholine receptor antibodies (AChRAb) to the main immunogenic region (MIR) of AChR alpha-subunit in the neuromuscular junction is the major pathogenesis of myasthenia gravis (MG).
Methods: A synthetic peptide of 10 amino acids corresponding to the MIR of human AChR was coupled with cellulose beads to make an antigen-specific immunoadsorbent (hMIR10-CB).
Results: The hMIR10-CB could remove AChRAb in MG sera by 40.3+/-2.3%, compared to a tryptophan nonspecific adsorbent Trp-CB by only 22.4+/-1.5% as determined in ELISA, and also showed good blood compatibility for blood cells, plasma ions and plasma proteins as checked in whole blood perfusion in rabbits.
Conclusions: The antigen-specific immunoadsorbent hMIR10-CB can serve as a potential candidate in the immunoadsorption treatment of MG.
Similar articles
-
Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum.J Immunol Methods. 2005 Aug;303(1-2):142-7. doi: 10.1016/j.jim.2005.04.013. J Immunol Methods. 2005. PMID: 16040047
-
Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.Ann N Y Acad Sci. 2008;1132:291-9. doi: 10.1196/annals.1405.017. Ann N Y Acad Sci. 2008. PMID: 18567880
-
Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy.J Neuroimmunol. 2005 Feb;159(1-2):183-91. doi: 10.1016/j.jneuroim.2004.10.002. Epub 2004 Nov 23. J Neuroimmunol. 2005. PMID: 15652418
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
-
Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.J Neuroimmunol. 2008 Sep 15;201-202:95-103. doi: 10.1016/j.jneuroim.2008.06.020. Epub 2008 Jul 29. J Neuroimmunol. 2008. PMID: 18667243 Review.
Cited by
-
Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis.Neural Regen Res. 2014 Apr 15;9(8):851-6. doi: 10.4103/1673-5374.131611. Neural Regen Res. 2014. PMID: 25206900 Free PMC article.
-
Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis.Neurosci Bull. 2012 Oct;28(5):469-74. doi: 10.1007/s12264-012-1256-0. Epub 2012 Jul 4. Neurosci Bull. 2012. PMID: 22961471 Free PMC article.
-
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.Drugs. 2021 Nov;81(17):1969-1981. doi: 10.1007/s40265-021-01621-y. Epub 2021 Nov 8. Drugs. 2021. PMID: 34748189 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
